This Nov 3rd, join us for the third edition of Business of Cannabis: New York at the New York Academy of Medicine. A day long leadership summit focused on retail, investment & policy across New York and North America. Tickets on-sale now – www.cannabisnewyork.live
Health Canada has announced it is making changes to the process of adding sale authorisation of cannabis products to processing licenses.
In a bid to improve the country’s cannabis program, Health Canada has confrimed it will phase out “inspections for authorized activities change requests to add the activity of sale of extract, edible, and topical cannabis products”.
Submission requirements, including: inner and outer labels; photos of lots; completed packaging records; a master list of standard operating procedures; evidence of child resistance requirements on packaging; and, proof that products have been tested using validated test methods, will no longer be required.
Additionally, inspections prior to the issuance of an amendment to a processing licence to authorise a sale will no longer be required.
Health Canada has also stated that licence holders who are granted the authorisation to sell will be prioritised for regular inspections using a risk-based approach, and that it will no longer carry out in-person compliance promotion sessions and instead will provide compliance promotion material online.
The amendments will apply to micro and standard processing licence holders.
The body stated: “The decision for the above program changes was part of several progressive changes made to Health Canada’s approach to the authorization of sale activities for licence holders. No changes are being made to the regulatory requirements.”
The changes came into force from 1 October, 2023, and will continue to be assessed under the previous process.
